Abstract:Background: Nobiletin (NOB), a polymethoxy flavonoid, possesses anti-cancer and anti-inflammatory activities, has been reported that it played role in anti-osteoporosis treatment. However, previous research did not focus on practical use due to lack of hydrophilicity and cytotoxicity at high concentrations. The aim of this study was to develop a therapeutic formulation for osteoporosis based on the utilization of NOB.Methods: In this study, NOB-loaded poly(ethylene glycol)-block-poly(e-caprolactone) (NOB-PEG-PCL) was prepared by dialysis method. The effects on osteoclasts and anti-osteoporosis functions were investigated in a RANKL-induced cell model and ovariectomized (OVX) mice.Results: Dynamic light scattering and transmission electron microscopy examination results revealed that the NOB-PEG-PCL had a round shape, with a mean diameter around 124 nm. The encapsulation efficiency and drug loading were 76.34 +/- 3.25% and 7.60 +/- 0.48%, respectively. The in vitro release of NOB from NOB-PEG-PCL showed a remarkably sustained releasing characteristic and could be retained at least 48 hrs in pH 7.4 PBS. Anti-osteoclasts effects demonstrated that the NOB-PEG-PCL significantly inhibited the formation of tartrate-resistant acid phosphatase (TRAP)-positive multinuclear cells stimulated by RANKL. Furthermore, the NOB-PEG-PCL did not produce cytotoxicity on bone marrow-derived macrophages (BMMs). The mRNA expressions of genetic markers of osteoclasts including TRAP and cathepsin K were significantly decreased in the presence of NOB-PEG-PCL. In addition, the NOB-PEG-PCL inhibited OC differentiation of BMMs through RANKL-induced MAPK signal pathway. After administration of the NOB-PEG-PCL, NOB-PEG-PCL prevented bone loss and improved bone density in OVX mice. These findings suggest that NOB-PEG-PCL might have great potential in the treatment of osteoporosis.Conclusion: The results suggested that NOB-PEG-PCL micelles could effectively prevent NOB fast release from micelles and extend circulation time. The NOB-PEG-PCL delivery system may be a promising way to prevent and treat osteoporosis.

Nitric Oxide-Donating Genistein Prodrug: Design, Synthesis, and Bioactivity on Mc3t3-E1 Cells

NO-donating Genistein Prodrug Alleviates Bone Loss in Ovariectomized Rats

In Vivo and in Vitro Activity of Genistein in Osteoporosis

A Novel Prenylflavonoid Icariside I Ameliorates Estrogen Deficiency-Induced Osteoporosis Via Simultaneous Regulation of Osteoblast and Osteoclast Differentiation

Synthesis and Cytotoxicity Evaluation of 3-Amino-2-hydroxypropoxygenistein Derivatives.

Study on the Mechanism of Naringin in Promoting Bone Differentiation: in Vitro and in Vivo Study

Genistein stimulates the osteoblastic differentiation via NO/cGMP in bone marrow culture.

Nobiletin-Loaded Micelles Reduce Ovariectomy-Induced Bone Loss By Suppressing Osteoclastogenesis

Gelatin-siloxane nanoparticles to deliver nitric oxide for vascular cell regulation: synthesis, cytocompatibility, and cellular responses.

[Effects of Genistein on NOS, GSH-Px Activities and NO, GSH, MDA Contents in MCF Human Breast Cancer Cells].

Phytoestrogen Genistein Supplementation Increases Enos and Decreases Caveolin-1 Expression in Ovariectomized Rat Hearts.

Bone-Targeted Biomimetic Nanogels Re-Establish Osteoblast/Osteoclast Balance to Treat Postmenopausal Osteoporosis

[Effects of Genistein on Cell Proliferation and Differentiation in Human Osteoblast].

Development of three-component conjugates: to get nano-globes with porous surfaces, high in vivo anti-osteoporosis activity and minimal side effects

Novel nano-materials, RGD-tetrapeptide-modified 17β-amino-11α-hydroxyandrost-1,4-diene-3-one: synthesis, self-assembly based nano-images and in vivo anti-osteoporosis evaluation

Design, Synthesis, and Biological Evaluation of Novel Nitric Oxide Releasing Dehydroandrographolide Derivatives.

CeO2 Nanoparticle Bioactive Materials Promote MG-63 Osteogenic Differentiation and Antioxidant Activity Through NRF2 Signaling

Comparison of Neoeriocitrin and Naringin on Proliferation and Osteogenic Differentiation in MC3T3-E1.

Novel Anticancer Oridonin Derivatives Possessing a Diazen-1-ium-1,2-diolate Nitric Oxide Donor Moiety: Design, Synthesis, Biological Evaluation and Nitric Oxide Release Studies.

Genistein Inhibits Osteoclastic Differentiation of RAW 264.7 Cells via Regulation of ROS Production and Scavenging

Synthesis of N-methylpyridine-chlorofuranformamide analogs as novel OPG up-regulators and inhibitors of RANKL-induced osteoclastogenesis